We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
RAI3 expression is not associated with clinical outcomes of patients with non-small cell lung cancer.
- Authors
Melling, Nathaniel; Reeh, Matthias; Ghadban, Tarik; Tachezy, Michael; Hajek, André; Izbicki, Jakob Robert; Grupp, Katharina
- Abstract
Purpose: Retinoic acid inducible protein 3 (RAI3) has been suggested as prognostic biomarker in several cancer types. The present study aimed to examine the role of RAI3 expression in non-small cell lung cancers (NSCLCs). Methods: RAI3 protein expression was evaluated by immunohistochemistry in tissue microarray (TMA) sections from a retrospective cohort of more than 600 surgically resected NSCLCs and results were compared with clinicopathological features and follow-up data. Results: While membranous RAI3 immunostaining was always strong in benign lung, strong RAI3 staining was only detectable in 14.7% of 530 interpretable NSCLCs. Within NSCLC subtypes, immunostaining intensity for RAI3 was significantly decreased in large cell lung cancers (LCLCs) and squamous cell carcinomas (SQCCs) relative to lung adenocarcinomas (LUACs) (P < 0.0001 each). However, RAI3 staining was neither associated with pathological features of NSCLCs nor with survival of patients (P = 0.6915). Conclusion: Our study shows that RAI3 expression was not associated with clinical outcomes of NSCLC patients and cannot be considered as prognostic marker in lung cancer patients.
- Subjects
NON-small-cell lung carcinoma; PROTEIN expression; SQUAMOUS cell carcinoma; PROGNOSIS; LUNG cancer
- Publication
Journal of Cancer Research & Clinical Oncology, 2023, Vol 149, Issue 9, p6549
- ISSN
0171-5216
- Publication type
Article
- DOI
10.1007/s00432-023-04631-3